Next Day Disclosure Return
Filed with HKEX · Stock code 6887 · · 5 pages · English
Sunshine Lake Pharma Co., Ltd. on 6ix
Earlier from Sunshine Lake Pharma
- Inside information filing with the CSRC in relation to the proposed implementation of h share full circulation
- Lannett Company, Lanexa Biologics and Sunshine Lake Pharma announce FDA Approval of LANGLARA™ an Interchangeable Biosimilar of Lantus® (insulin glargine)
- Sunshine Lake Pharma Co., Ltd. (06887.HK) Completes Listing, Market Capitalisation Expected to Rapidly Surpass RMB 50 Billion
Later from Sunshine Lake Pharma
- Interim Report 2026
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement Insulin Degludec and Insulin Aspart Injection obtained marketing approval from the china national medical products administration
- Change of company secretary, authorized representative and process agent
Follow Sunshine Lake Pharma into a list and get an email when it puts out news.
Follow Sunshine Lake Pharma